NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$13.77
+0.34 (+2.53%)
Close of Nov 06, 2026 · end-of-day data
LFST 8-K filings in 2024
Every material Form 8-K Lifestance Health filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LifeStance's subsidiary entered a new credit agreement with Capital One as administrative agent, funding a $290.0 million senior secured term loan on December 19, 2024 and establishing a $100.0 million revolving facility. Proceeds were used to repay and terminate the existing credit agreement dated May 4, 2022, and both facilities mature on the fifth anniversary of the closing date.
Term loan facility of $290.0 million, funded on December 19, 2024, with interest at adjusted term SOFR (0.00% floor) plus 3.00% or a base rate plus 2.00%
Revolving facility commitments of up to $100.0 million, with a 0.45% per annum undrawn commitment fee subject to leverage-based stepdowns
Proceeds used to repay all outstanding loans under the May 4, 2022 credit agreement, which was terminated
Obligations are guaranteed by Holdings and certain subsidiaries and secured by substantially all assets of the Borrower, Holdings and subsidiary guarantors
LifeStance Health Group reported third-quarter 2024 revenue of $312.7 million, up 19% from a year earlier, and a net loss of $6.0 million, down from $61.6 million. The company raised its full-year 2024 revenue, Center Margin and Adjusted EBITDA expectations, which gives shareholders a higher outlook than before the report.
Q3 2024 revenue was $312.7 million, up 19%; Adjusted EBITDA was $30.7 million, up 110%
Net loss narrowed to $6.0 million from $61.6 million in Q3 2023
Full-year 2024 revenue guidance raised to $1.228 billion to $1.248 billion; Adjusted EBITDA guidance raised to $105 million to $115 million
Company continues to expect positive Free Cash Flow for full-year 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lifestance Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →